Mawdsleys’ clinical trials division, Wellspring, has further developed contacts in the international market, as they recently attended Bangalore Bio, India’s premier biotechnology event.
Nick Hill, Mawdsleys’ unlicensed medicines manager, and a team from the clinical trials division partnered up with a remit to demonstrate to pharma and biotech companies how the group can help them go ‘full circle’ from clinical trials to prelaunch.
Nick Hill explains: “One of the main purposes of attending the event was to set up exclusive partnerships with pharma companies to be the sole supplier of their pre-launch products. Prior to our visit to India, we had incredible support from the UK government’s trade and investment division (UKTI), who set up appointments for us in advance, with interested companies in the Indian biotech and CRO industries.
“During our seven day visit, we had the opportunity to present to the decision makers of about 60 companies and were literally bombarded with people wanting to talk to us. All in all, Bangalore Bio was a huge success and demonstrated how the Mawdsleys group can provide a ‘full circle’ service to pharmaceutical companies and biotechs worldwide.”